Columbia Laboratories, Inc. Schedules Fourth Quarter and Year End 2001 Earnings Release and Conference Call.

Business Editors & Health/Medical Writers

LIVINGSTON, N.J.--(BUSINESS WIRE)--March 18, 2002

Columbia Laboratories, Inc. (AMEX:COB) today announced that it plans to release its fourth quarter and year end 2001 earnings on March 21, 2002 after the close of regular trading hours and then host a conference call on March 22, 2002 at 9:00 a.m. (Eastern Time) to review the results. Investors and interested parties are invited to listen to the conference call by dialing [phone] domestically, and [phone] for international participants, or via a live Internet broadcast at http://www.vcall.com/EventPage.asp?ID=80993. Mr. Fred Wilkinson, President and Chief Executive Officer, James Apostolakis, Vice Chairman and David Weinberg, Chief Financial Officer, of Columbia Laboratories will host the conference call.

A replay of the conference call will be available from March 22, 2002, beginning at 11:30 a.m. and ending on April 4, 2002 at 11:30 p.m. Investors and interested parties may dial [phone] or [phone] and enter access number 20458095. Additionally, the webcast will be archived for a period of 90 days following the conference call at http://www.vcall.com/EventPage.asp?ID=80993.

Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to research and development of women's health care and endocrinology products, including those intended to treat infertility, dysmenorrhea, endometriosis and hormonal deficiencies. Columbia is also developing hormonal products for men and a buccal delivery system for peptides. Columbia's products primarily utilize the company's patented bioadhesive delivery technology.

This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management team. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Such risks and uncertainties include, among other things, timely and successful completion of clinical studies, competitive economic and regulatory factors in the pharmaceutical and health care industry, the outcome of pending litigation, general economic conditions and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission.